Last reviewed · How we verify
Ligerium (MECLORALUREA)
Ligerium (generic name: MECLORALUREA) is a drug. It is currently in Phase 2 development.
Ligerium works by interacting with a specific molecular target to produce a therapeutic effect.
Ligerium (MECLORALUREA) is a small molecule compound with unknown target and drug class. Its commercial status is unclear, and it is not FDA approved for any indications. As a small molecule, it is likely to be administered orally, but its pharmacokinetic properties such as half-life and bioavailability are unknown. The compound's ownership and off-patent status are also unclear. Further research is needed to determine its potential therapeutic applications and safety profile.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MECLORALUREA |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have locks on them, and Ligerium is a key that fits into one of those locks. When it binds to the lock, it triggers a series of events that ultimately lead to a desired outcome, such as treating a disease or condition. This is a simplified explanation of how Ligerium works at a molecular level.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ligerium CI brief — competitive landscape report
- Ligerium updates RSS · CI watch RSS
Frequently asked questions about Ligerium
What is Ligerium?
How does Ligerium work?
What is the generic name of Ligerium?
What development phase is Ligerium in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing